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A B S T R A C T
Status epilepticus (SE) is a frequent neurological emergency requiring immediate treatment. Therapy
usually requires intravenous anticonvulsive medication. Lacosamide is a novel anticonvulsant drug that
is available as infusion solution. We describe seven patients with focal SE who were treated with
intravenous Lacosamide. All patients in our case series were unsuccessfully treated with other
antiepileptic drugs before Lacosamide i.v. was added. In all cases, SE was terminated within 24 h after
Lacosamide. There were no serious side effects or adverse events attributable to Lacosamide i.v. Our data
suggest that Lacosamidemight be an effective add-on treatment, if standard drugs fail or are unsuitable.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The status epilepticus (SE) is a frequent neurological emergency
requiring immediate treatment. SE is deﬁned as a single clinical
seizure lastingmore than 30 min or repeated seizures over a period
of more than 30 min without intervening recovery of conscious-
ness.1 It may present as convulsive or non-convulsive SE. Clinical
symptoms and EEG changes may be generalized, lateralized, or
focal. The average incidence of SE is at least 20/100,000 in the
western economies. The highest incidence rates could be found in
patients older than 60 years and in infants younger than 12
months.2 Current guidelines recommend the initial use of
benzodiazepines, preferably Lorazepam (LZP), followed by Phe-
nytoin (PHT). If SE remains refractory to ﬁrst-line treatment, the
use of barbiturates, Propofol or Midazolam is recommended.3,4
Narcotic doses of these medications routinely require patients to
receive artiﬁcial ventilation and intensive therapy. Therefore, a less
aggressive approach may be more beneﬁcial for patients with
respiratory or circulatory problems. Valproate (VPA) and Levetir-
acetam (LEV) are two anticonvulsant drugs that are available as
intravenous formulation and are considered as alternative
therapeutic options.5 Lacosamide (LCM) is a novel anticonvulsant
agent that has been approved for add-on therapy in patients with
partial and secondary generalized seizures by the European drug* Corresponding author. Tel.: +49 251 83 45845; fax: +49 251 83 45847.
E-mail address: albersjo@uni-muenster.de (J.M. Albers).
1 Equal contribution.
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.017licensing authority EMEA.2 Intravenous LCM has biovailability
comparable to that of the oral formulation and has been approved
for partial and generalized seizures as replacement when oral
administration is not possible. LCM as a parenteral solution could
potentially be useful for patients who require rapid loading of
anticonvulsants, such as SE.
We describe seven patients who were successfully treated with
Lacosamide intravenously on our neurological intensive care unit
with SE resistant to standard ﬁrst-line therapy.
2. Results
SE was deﬁned as ongoing automotor or tonic-clonic symp-
toms, or repetitive seizure without recovery of consciousness in
between for at least 30 min, and/or conﬁrmation of an EEG status
pattern on routine 10–20 EEG. ‘‘Refractory SE’’ was deﬁned as
ongoing SE despite adequate ﬁrst-line treatment with benzodia-
zepines and/or phenytoin. All patients received brain CT or MRI
scans on the day of admission. SE was considered responsive to
LCM if EEG status resolved within 24 h after the start of LCM-i.v.
and no further antiepileptic agents were added to the treatment
protocol during this time period.
2.1. Patient one
A 77-year-old male patient with a history of atrial ﬁbrillation,
hypertension and diabetes mellitus was admitted to the depart-
ment of neurosurgery after he had collapsed at home. Intubation
and artiﬁcial ventilation was started by the emergency physician.vier Ltd. All rights reserved.
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hemispheric subdural hematoma with a 9 mm midline shift
requiring urgent hematoma evacuation and decompressive
craniectomy. 24 h after surgery, the patient experienced two right
hemispheric focal, tonic-clonic seizures, which were treated by
intravenous VPA (1500 mg/d). In the following course the patient
remained comatose, despite cessation of clonic symptoms, the EEG
showed ongoing right hemispheric electrographic SE. Propofol (2%)
was used to suppress epileptiform discharges, however, after
discontinuation, focal status reappeared. Since, the patient
remained comatose throughout treatment with LEV (2  3 g/d)
and Topiramat 2  200 mg/d (TPM) were added, without improv-
ing the EEG status pattern. Therefore, 21 days after the ﬁrst focal
seizure, the patient received LCM intravenously (400 mg initial
bolus, then 400 mg daily). Electrographic SE resolved within 24 h,
when the patient woke up, he suffered from hemiparesis on the
left. At least he was sent to a rehabilitation centre.
2.2. Patient two
This 63-year-old male patient with a history of ischemic stroke
was admitted to our department after hewas picked unconsciously
by police. His history contained no othermedical conditions and no
known allergies or illnesses. CCT showed a right hemispheric grain,
due to a stroke. The analysis of liquor was normal. The EEG showed
right hemispheric status epilepticus. PHT (20 mg/kg/30 min) was
used to suppress epileptiform discharges. Because of ongoing SE
controlled by continuous EEG monitoring, Propofol (2%) was used
12 h after ﬁrst application of PHT. In the following course the
patient remained comatose and EEG showed right hemispheric
status epilepticus after discontinuation of Propofol. 48 h after
admission narcosis was continued with Midazolam (0.2 mg/kg/h)
and a treatmentwith LEV (2  2 g/d)was initiated. The EEG control
after further 24 h showed ongoing SE that resolved within 24 h
after LCM-i.v. (400 mg bolus, 400 mg daily, thereafter). The patient
woke up rapidly without a signiﬁcant neurological deﬁcit.
2.3. Patient three
The 80 years old patient with a history of hypertension, COPD
and alcohol abuse was admitted to our department after he
experienced a ﬁrst focal, left hemispheric automotor seizure. The
emergency team had already administered 10 mg intravenous
diazepam during transport. Emergency laboratory tests showed a
high serum-concentration of theophyllin. The CCT appeared
normal. Continuous EEG monitoring was started approximately
2 h after beginning of the symptoms and initially showed rhythmic
slowing and spiking in the left hemisphere.
Administration of a total of 2 g LEV within 24 h (2  2 g/d
thereafter) resulted in amplitude reduction, but not in cessation of
rhythmic epileptiform activity. The patient remained comatos and
Midazolam (0.2 mg/kg/h) was used to suppress epileptiform
discharges, however, after discontinuation, focal status reap-
peared. Therefore, 48 h after the ﬁrst focal seizure, the patient
received TPM (3  50 mg/d)which had no effect. 48 h after the ﬁrst
application of TPM Lacosamid was started intravenously (400 mg
bolus, 400 mg daily thereafter). Both, clinically and electroen-
cephalographically focal SE resolved within 24 h thereafter.
Because of serve COPD the weaning appeared difﬁcult, when the
patient was discharged form our hospital he followed simple
challenges but still needed artiﬁcial ventilation.
2.4. Patient four
The 83 years old female patient with a history of epilepsy,
dementia, alcohol abuse and mamma carcinoma was admitted toour department because of a generalized tonic-clonic seizure.
Anticonvulsive therapy was LEV (1 g/d) and VPA. Emergency
laboratory tests showed a therapeutic serumVPA level. 4 days after
admission, the patient experienced a right hemispheric focal,
tonic-clonic epileptic seizure, although the therapy with LEV had
been exalted (2  3 g/d) since the day of admission. CCT showed a
right hemispheric subdural hematoma, which made hematoma
evacuation necessary. After neurosurgery the patient remained
comatose, EEG showed right hemispheric status epilepticus.
Therefore, Propofol (2%) and TPM (2  400 mg/d) were used
successfully to suppress epileptiform discharges. 7 days after the
application of Propofol and TPM the focal status reappeared, both
clinically and electroencephalographically. Therefore, the patient
received LCM intravenously (400 mg bolus, 400 mg daily thereaf-
ter). Remarkably, both clinically and electroencephalographically
focal SE resolved within 24 h thereafter.
2.5. Patient ﬁve
This 62 years old male patient was admitted to our hospital,
because of a large right hemispheric subdural hematoma, which
needed urgent hematoma evacuation and decompressive cra-
niectomy. Immediately after surgery, the patient experienced a
right hemispheric tonic-clonic seizure, which was treated by
intravenous VPA (3  900 mg/d). In the following 2 h the patient
remained comatose, despite cessation of clonic symptoms, the EEG
showed ongoing right hemispheric and for short times generalized
electrographic SE, which were treated by intravenous LEV
(2  2 g). Moreover, Propofol (2%) was used to suppress epilepti-
form discharges. 24 h later Propofol was discontinuated and focal
status reappeared. Therefore, the patient received LCM intrave-
nously (400 mg bolus, 400 mg daily thereafter). Both, clinically
and electroencephalographically focal SE, resolved within 24 h
thereafter. The patient woke up rapidly without a signiﬁcant
neurological deﬁcit.
2.6. Patient six
This 61 years old male patient was admitted to our department
because of a right hemispheric focal status epilepticus. He had a
history of diabetes mellitus and hepatic transplantation after
alcoholic cirrhosis (Child B) in 2009.
After an intracerebral bleeding in 2009 he experienced one focal
epileptic seizure, therefore he takes a medication with LEV (1 g/d).
This effective anticonvulsive medication has been discontinuated
because of increasing transaminase enzymes, just before the
admission to our hospital. Administration of a total of 2 g LEV
within 24 h and 2  1 g/d thereafter did not resulted in cessation of
clinically status epileptius and rhythmic epileptiform activity. For
that reason the patient received a bolus of 400 mg LCM and both,
clinically and electroencephalographically focal SE, resolved
within 1 h thereafter.
2.7. Patient seven
The 33 years old male patient with a history of symptomatic
epilepsy due to an infantile brain damage was admitted to our
department because of a generalized epileptic seizure. The patient
had a premedication with Phenobarbital (3  75 mg/d). The
emergency physician started artiﬁcial ventilation and a therapy
with Midazolam (0.2 mg/kg/h). The following EEG showed burst
suppression pattern. After administration of a total of 2 g LEV and
2  1 g/d thereafter the therapy with Midazolam was disconti-
nuated and the EEG showed delta wave activity. 4 days thereafter,
focal right hemispheric SE reappeared clinically and detected by
EEG. Although the therapywith LEVwas exalted (3 g/d) and SEwas
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one week thereafter. For that reason the patient received LCM
intravenously (400 mg bolus, 400 mg daily thereafter) and both
clinically and electroencephalographically focal SE resolvedwithin
24 h thereafter.
3. Discussion
Status epilepticus is a neurological emergency that requires
rapid i.v. anticonvulsant treatment. However, only few of the
available drugs are explicitly licensed for treatment of status
epilepticus, and most of them such as PHT or thiopental carry a
high risk of adverse events or require artiﬁcial ventilation, or both.2
Previous reports have suggested that intravenous LEV and VPA are
effective and well tolerated as treatment for SE.6–8 All patients in
our case series were treated with either LEV or VPA (or both) in
combination with TPM, benzodiazepines and Propofol, without
control of clinical or electrographic SE. In all cases, SE was
terminated within 24 h after application of LCM i.v. As all patients
were simultaneously treatedwith other antiepileptic drugs (AEDs),
termination of SE is most likely attributable to additional effects of
LCM to its co-medications. To our knowledge until now there are
only few case reports which describe a possible effectiveness of
LCM in focal SE.9,10 In our cases no side effects or interactions
occurred which were attributable to LCM. There were no
signiﬁcant changes in heart rate or blood pressure. No increase
of catecholamine dose was required and no cardiac arrhythmias
were noted.
Our data shows that LCM might be an effective add-on
treatment, if standard drugs fail or are unsuitable. Intravenous
LCM is easy to handle, and has the same safety proﬁle as its oralformulation. However, prospective and controlled trials are
needed to assess the efﬁcacy and safety in particular in long-
term application of LCM for this indication.
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